Cargando…
Potential clinical implications of BRAF mutations in histiocytic proliferations
For a growing number of tumors the BRAF V600E mutation carries therapeutic relevance. In histiocytic proliferations the distribution of BRAF mutations and their relevance has not been clarified. Here we present a retrospective genotyping study and a prospective observational study of a patient treat...
Autores principales: | Bubolz, Anna-Maria, Weissinger, Stephanie E., Stenzinger, Albrecht, Arndt, Annette, Steinestel, Konrad, Brüderlein, Silke, Cario, Holger, Lubatschofski, Anneli, Welke, Claudia, Anagnostopoulos, Ioannis, Barth, Thomas F. E., Beer, Ambros J., Möller, Peter, Gottstein, Martin, Viardot, Andreas, Lennerz, Jochen K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147306/ https://www.ncbi.nlm.nih.gov/pubmed/24938183 |
Ejemplares similares
-
Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells
por: Steinestel, Konrad, et al.
Publicado: (2014) -
Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma
por: Lennerz, Jochen K., et al.
Publicado: (2015) -
GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma
por: Feld, Fenja M, et al.
Publicado: (2015) -
Expression of Abelson Interactor 1 (Abi1) Correlates with Inflammation, KRAS Mutation and Adenomatous Change during Colonic Carcinogenesis
por: Steinestel, Konrad, et al.
Publicado: (2012) -
Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
por: Zanwar, Saurabh, et al.
Publicado: (2022)